Figure 4: A case with left refractory diabetic macular edema (DME) 3 months after grid laser and improvement in macular thickness and best-corrected visual acuity (BCVA) after 3-monthly ranibizumab injections that persisted 6 months from the fi rst injection. (a) Patient with left refractory DME after focal grid laser (BCVA: 6/36) (b) Left eye after 1 month from the fi rst injection (BCVA: 6/24) (c) The left eye after 1 month from the second injection (BCVA: 6/24) (d) After 1 month from the third injection (BCVA: 6/12) (e) Left eye 6 months from the fi rst injection (BCVA: 6/9)